Send to

Choose Destination
Alzheimers Dement (Amst). 2019 Apr 16;11:327-332. doi: 10.1016/j.dadm.2019.02.004. eCollection 2019 Dec.

Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies.

Author information

Vita-Salute San Raffaele University, Milan, Italy.
In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Nuclear Medicine Unit, San Raffaele Hospital, Milan, Italy.
European Institute for Molecular Imaging, University of Münster, Münster, Germany.
Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.



A rapid transition from a clinical-based classification to a pathology-based classification of neurodegenerative conditions, largely promoted by the increasing availability of imaging biomarkers, is emerging. The Framework for Innovative Multi-tracer molecular Brain Imaging, funded by the EU Joint Program - Neurodegenerative Disease Research 2016 "Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration," aimed at providing a roadmap for the applications of established and new molecular imaging techniques in dementia.


We consider current and future implications of adopting a pathology-based framework for the use and development of positron emission tomography techniques.


This approach will enhance efforts to understand the multifactorial etiology of Alzheimer's disease and other dementias.


The availability of pathology biomarkers will soon transform clinical and research practice. Crucially, a comprehensive understanding of strengths and caveats of these techniques will promote an informed use to take full advantage of these tools.


Amyloid; Neuroinflammation; PET molecular imaging; Protheinopathies; Radiotracers; Tau

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center